Building the evidence to move light-controlled oncology forward.
At GenLumina, we’re focused on developing light-activated cancer treatments. By combining our nanocluster technology with antibodies, biomarkers, peptides and advanced imaging techniques, we aim to precisely target and treat cancer cells.
From proof of concept to clinical readiness.
Each stage adds the formulation, safety, efficacy, manufacturing and regulatory evidence required to progress the platform responsibly.
Proof-of-concept studies
- Formulation
- In vitro & in vivo validation
- Collaboration with LUMC
- GLP setup
Preclinical
- GLP / CMC
- Dosage-range finding
- Pharmacokinetics & dynamics (PK/PD)
IND-ready
- Safety & efficacy validation package for EMA/FDA
- Dosage optimisation for efficacy
- Regulatory pre-submission
First in human
- Safety validation in a small patient population
Lead with one indication. Expand through the platform.
GenLumina is building evidence in colorectal cancer while preserving the adaptability to evaluate other tumour types with suitable targeting and light-delivery strategies.
Colorectal cancer treatment
Starting with colorectal cancer, we are proving the efficacy of our light-activated technology in real-world applications.
Other cancer types
We are utilizing our platform’s adaptability to expand to a wide range of cancers, aiming to make a greater impact on patients’ lives.
Different expertise for each next step.
Proof-of-concept research
Work with GenLumina across cancer indications using antibodies, peptides, biomarkers or imaging techniques.
Clinical translation
Bring oncology and pharmaceutical development expertise to the design of early-stage clinical studies.
Combination potential
Explore how the platform can complement surgery, radiotherapy, immunotherapy and other treatment pathways.
Why selective local control matters.
Clinical collaborators highlight the potential value of more selective, less toxic treatment approaches across several cancer settings.
“Given the potential of GenLumina’s light-activated therapy to target tumors effectively, improve surgical precision, and minimize collateral tissue damage, I believe this technology holds great promise for advancing cancer treatment, particularly for colorectal, ovarian, and pancreatic cancers.”
“A more effective photodynamic treatment would make tens of thousands of surgical procedures with complications, disturbing scars, and multiple hospital visits unnecessary every year.”
“A better, more tumor-selective and less toxic treatment for skin cancers is eagerly awaited. The light-activated DNA-silver constructs provide a new opportunity to explore highly selective treatment of superficial cancers.”
Bring your targeting biology or oncology expertise.
We can define a focused evaluation and jointly decide which evidence should unlock the next development step.